News Novartis raises mid-term sales outlook on pipeline promise Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets
News Eisai debuts biliary tract cancer drug in Japan Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
News Pfizer bags EU okay for haemophilia drug Hympavzi Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU
News FDA says no to Astellas' geographic atrophy drug Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US.
News Grifols linked to €7bn takeover offer from Brookfield Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends